Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2004

View Archived Issues

TAK-779, a novel immunosuppressant prolongs graft survival in mice

A novel JAK-3 inhibitor, NC-1153, increases graft survival and induces transplantation tolerance

Caspase -3 and -8 inhibition has therapeutic potential in lung transplantation

Array BioPharma highlights Q3 FY 2004 developments

Pharmacyclics continues to advance multiple clinical development programs with Xcytrin

Rigel's development programs proceeding according to plan

Preclinical safety and efficacy of chimeric yellow fever vaccine in non-human primates

Successful synthesis of radiolabeled ENT-103

New phase II trial for Serostim in HARS

ND-1251 enters phase I for depression

Avigen to focus resources on neurological drug candidates

Sanctura receives FDA approval

Not-approvable letter for Pozen's MT-100

ViroLogic and ACLARA BioSciences to merge

PA-457 completes single-dose phase I trial

Second portion of Entereg NDA submitted

First clinical study of ferumoxytol under NCI clinical trial agreement

Cloretazine enters phase II trial for recurrent glioma

NIAID supports phase I trial of Vical's DNA-based anthrax vaccine

Gamunex shown to be safe and efficacious in prospective ITP study

Low-dose RWJ-58643 inhibits the effects of allergen challenge in patients with allergic rhinitis

CDP-870 shows potential in the treatment of asthma

SB-733210, a novel dual NK2/NK3 receptor antagonist with broncholytic and antitussive activity

Sales approval for cefditoren pivoxil in Spain

Janssen researchers describe two series of delta opioid receptor modulators

cPLA2alpha is a novel therapeutic target for asthma therapy

Aventis claims hormone-sensitive lipase inhibitors and their use as antidiabetic agents

Myriad Genetics presents new NK1 antagonists for emesis, pain, etc.

Dual D2/5-HT1A ligands with potential in schizophrenia therapy

Novel macrocyclic lactam with antimicrobial and antitumor activity

Merck KGaA patent covers new factor Xa and factor VIIa inhibitors

New COX-2 inhibitors prepared and tested by Korean team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....